<h3>在这个假期季节，TipRanks 限时 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>Astria Therapeutics (ATXS) 的公告现已发布。</p>
<p>2025 年 10 月 14 日，Astria Therapeutics 与 BioCryst Pharmaceuticals 及其子公司签署了合并协议，子公司将合并入 Astria，使 Astria 成为 BioCryst 的全资子公司，BioCryst 已提交相关注册声明，而 Astria 则已发布关于该交易的最终代理声明以供股东投票。在 2025 年 12 月中旬，纽约州法院提起了两起股东诉讼，指控 Astria 及其董事会在合并中疏忽地发布了虚假和误导性的注册声明，并寻求禁令救济、损害赔偿和费用，但公司已驳回这些索赔，认为其没有依据，辩称任何所谓的错误陈述都不重要或不可诉，并承诺将积极捍卫诉讼，同时继续推进合并进程。</p>
<p>(ATXS) 股票的最新分析师评级为持有，目标价为 13.00 美元。要查看 Astria Therapeutics 股票的完整分析师预测列表，请访问 ATXS 股票预测页面。</p>
<p><strong>Spark 对 ATXS 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，ATXS 的评级为中性。</p>
<p>Astria Therapeutics 的股票评分反映了其作为一家开发阶段生物技术公司的地位。强劲的资产负债表提供了财务稳定性，但缺乏收入和不断增加的亏损带来了重大风险。混合的技术指标和估值挑战进一步加剧了谨慎的前景。</p>
<p>要查看 Spark 对 ATXS 股票的完整报告，请点击这里。</p>
<p><strong>关于 Astria Therapeutics 的更多信息</strong></p>
<p>Astria Therapeutics, Inc. 是一家位于特拉华州的生物制药公司，其股份由公众股东持有，并由董事会监督，正受到 BioCryst Pharmaceuticals 的收购，完成计划中的合并后将成为全资子公司。</p>
<p><strong>平均交易量：</strong> 2,078,799</p>
<p><strong>技术情绪信号：</strong> 持有</p>
<p><strong>当前市值：</strong> 732.4M 美元</p>
<p>要对 ATXS 股票进行全面评估，请访问 TipRanks 的股票分析页面。</p>

BioCryst制药

<p>Astria Therapeutics 面临股东针对其与 BioCryst Pharmaceuticals 计划合并的诉讼。这些诉讼指控存在虚假和误导性的注册声明，寻求禁令救济和赔偿。Astria 否认这些指控，承诺在推进合并的同时捍卫诉讼。分析师对 Astria 的股票评级为持有，目标价为 13.00 美元，指出其财务稳定，但因缺乏收入和不断增加的亏损而对风险表示谨慎</p>

<h3>Claim 70% Off TipRanks This Holiday Season</h3>
<div class="lb-trans"><h3>在这个假期季节，TipRanks 限时 70% 折扣</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>An announcement from Astria Therapeutics ( (ATXS) ) is now available.</p>
<div class="lb-trans"><p>Astria Therapeutics (ATXS) 的公告现已发布。</p>
</div><p>On October 14, 2025, Astria Therapeutics entered into a merger agreement with BioCryst Pharmaceuticals and a BioCryst subsidiary under which the subsidiary will merge into Astria, leaving Astria as a wholly owned unit of BioCryst, and BioCryst has filed the related registration statement while Astria has issued a definitive proxy statement for a stockholder vote on the deal. In mid-December 2025, two stockholder lawsuits were filed in New York state court alleging that Astria and its board negligently issued a false and misleading registration statement regarding the merger and seeking injunctive relief, damages, and fees, but the company has rejected the claims as without merit, arguing that any alleged misstatements are not material or actionable and pledging to vigorously defend the litigation while continuing to move the merger process forward.</p>
<div class="lb-trans"><p>2025 年 10 月 14 日，Astria Therapeutics 与 BioCryst Pharmaceuticals 及其子公司签署了合并协议，子公司将合并入 Astria，使 Astria 成为 BioCryst 的全资子公司，BioCryst 已提交相关注册声明，而 Astria 则已发布关于该交易的最终代理声明以供股东投票。在 2025 年 12 月中旬，纽约州法院提起了两起股东诉讼，指控 Astria 及其董事会在合并中疏忽地发布了虚假和误导性的注册声明，并寻求禁令救济、损害赔偿和费用，但公司已驳回这些索赔，认为其没有依据，辩称任何所谓的错误陈述都不重要或不可诉，并承诺将积极捍卫诉讼，同时继续推进合并进程。</p>
</div><p>The most recent analyst rating on (ATXS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.</p>
<div class="lb-trans"><p>(ATXS) 股票的最新分析师评级为持有，目标价为 13.00 美元。要查看 Astria Therapeutics 股票的完整分析师预测列表，请访问 ATXS 股票预测页面。</p>
</div><p><strong>Spark’s Take on ATXS Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 ATXS 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，ATXS 的评级为中性。</p>
</div><p>Astria Therapeutics’ stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook.</p>
<div class="lb-trans"><p>Astria Therapeutics 的股票评分反映了其作为一家开发阶段生物技术公司的地位。强劲的资产负债表提供了财务稳定性，但缺乏收入和不断增加的亏损带来了重大风险。混合的技术指标和估值挑战进一步加剧了谨慎的前景。</p>
</div><p>To see Spark’s full report on ATXS stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 ATXS 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Astria Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Astria Therapeutics 的更多信息</strong></p>
</div><p>Astria Therapeutics, Inc. is a Delaware-based biopharmaceutical company, with its shares held by public stockholders and overseen by a board of directors, that is the target of an acquisition by BioCryst Pharmaceuticals, under which it would become a wholly owned subsidiary following completion of a planned merger.</p>
<div class="lb-trans"><p>Astria Therapeutics, Inc. 是一家位于特拉华州的生物制药公司，其股份由公众股东持有，并由董事会监督，正受到 BioCryst Pharmaceuticals 的收购，完成计划中的合并后将成为全资子公司。</p>
</div><p><strong>Average Trading Volume:</strong> 2,078,799</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 2,078,799</p>
</div><p><strong>Technical Sentiment Signal:</strong> Hold</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 持有</p>
</div><p><strong>Current Market Cap:</strong> $732.4M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 732.4M 美元</p>
</div><p>For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要对 ATXS 股票进行全面评估，请访问 TipRanks 的股票分析页面。</p>
</div>

Astria 因计划与 BioCryst 制药合并而面临股东诉讼